Thelansis

Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Outlook Thelansis’s “Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Neuromyelitis Optica Spectrum Disorder (NMOSD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? W...

  Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Outlook Thelansis’s “Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Neuromyelitis Optica Spectrum Disorder (NMOSD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Neuromyelitis Optica Spectrum Disorder (NMOSD) Overview Neuromyelitis optica spectrum disorder (NMOSD) presents as an autoimmune astrocytopathy targeting the central nervous system, characterized by inflammation primarily affecting the optic nerve and spinal cord, with potential involvement of the brainstem, notably the area postrema. While its etiology remains elus...

  Neuromyelitis optica spectrum disorder (NMOSD) presents as an autoimmune astrocytopathy targeting the central nervous system, characterized by inflammation primarily affecting the optic nerve and spinal cord, with potential involvement of the brainstem, notably the area postrema. While its etiology remains elusive, recent studies have distinguished NMOSD from multiple sclerosis (MS) in terms of disease mechanisms, clinical features, and therapeutic approaches. Whole-genome sequencing has identified certain genotypes predisposing individuals to NMOSD, notably major histocompatibility complexes such as HLA-DRB1*03:01, which exhibit similarities to systemic lupus erythematosus (SLE) rather than MS. The hallmark of NMOSD is the presence of IgG antibodies against aquaporin-4, detected in most patients, particularly in regions rich in aquaporin-4, such as the optic nerve, spinal cord, and area posttrauma. This autoimmune process mediated by aquaporin-4 antibodies leads to perivascula...